<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888793</url>
  </required_header>
  <id_info>
    <org_study_id>210405014</org_study_id>
    <nct_id>NCT04888793</nct_id>
  </id_info>
  <brief_title>Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study</brief_title>
  <official_title>Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite COVID-19 pandemic having started more than one year ago, there are still limited&#xD;
      treatment options for these patients, and over 145 million cases and 3 millions deaths have&#xD;
      ensued worldwide. Fortunately, SARSCoV2 vaccines have been developed at an unprecedented&#xD;
      pace. While the vaccination programs are still ongoing, early reports on efficacy are mainly&#xD;
      centered on healthy population. In Chile most people have received the inactivated Coronavac&#xD;
      vaccine. Data on the immune response after vaccination in immunocompromised patients is&#xD;
      lacking. Therefore, this study aims to evaluate the immune response after Coronavac vaccine&#xD;
      in 5 cohorts of immunocompromised patients and healthy controls. We will include patients&#xD;
      with cancer, HIV, solid organ transplant and patients receiving immunomodulatory agents for&#xD;
      rheumatic diseases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Actual">November 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of positive neutralizing antibodies 8 to12 weeks after Coronavac vaccine</measure>
    <time_frame>8 to12 weeks after Coronavac vaccine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing geometric mean titers 8 to12 weeks after Coronavac vaccine</measure>
    <time_frame>8 to12 weeks after Coronavac vaccine</time_frame>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Actual">260</enrollment>
  <condition>Covid19</condition>
  <condition>COVID-19 Vaccines</condition>
  <arm_group>
    <arm_group_label>Cancer Patients on active treatment</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bone marrow transplant patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Solid organ transplant recipients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatic disease patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serologic immune response evaluation</intervention_name>
    <description>Detection of total and neutralizing antibodies against SARS-CoV-2</description>
    <arm_group_label>Bone marrow transplant patients</arm_group_label>
    <arm_group_label>Cancer Patients on active treatment</arm_group_label>
    <arm_group_label>HIV patients</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>Rheumatic disease patients</arm_group_label>
    <arm_group_label>Solid organ transplant recipients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving care at the Red de Salud UC Christus in Santiago, Chile will be invited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group &lt; 3&#xD;
&#xD;
          -  Vaccination with 2 doses of Coronavac vaccine&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Previous SARS-CoV-2 infection&#xD;
&#xD;
          -  Vaccination with Coronavac more than 12 weeks before informed consent&#xD;
&#xD;
          -  Intravenous immunoglobulin therapy 60 days before informed consent&#xD;
&#xD;
          -  Any condition, that could interfere with the participant's participation during the&#xD;
             study in the opinion of the treating investigator.&#xD;
&#xD;
        Cancer Cohort&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of cancer in the previous 5 years (consistent biopsy is required).&#xD;
&#xD;
          -  Life expectancy more than 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Bone marrow transplant, solid organ recipient, HIV, immunosuppressant treatment for&#xD;
             other condition.&#xD;
&#xD;
        Bone Marrow Transplant Cohort&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Bone marrow transplant between January 2019 and December 2020&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other cancer diagnosis during the last 5 years, solid organ recipient, HIV,&#xD;
             immunosuppressant treatment for other condition.&#xD;
&#xD;
        Solid Organ Recipient Cohort:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Liver, kidney or heart transplant between January 2019 and December 2020&#xD;
&#xD;
          -  Active immunosuppressant treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Cancer diagnosis during the last 5 years, bone marrow transplant, immunosuppressant&#xD;
        treatment for other condition, HIV&#xD;
&#xD;
        HIV Cohort:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  CD4 &lt;= 500 cels/mm3 documented one year before study enrollment&#xD;
&#xD;
          -  Active antiretroviral therapy&#xD;
&#xD;
          -  Viral load &lt; 200 copies/ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cancer diagnosis during the last 5 years, bone marrow transplant or solid organ&#xD;
             recipient, immunosuppressant treatment.&#xD;
&#xD;
        Rheumatic Disease Cohort&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis,&#xD;
             relapsing polychondritis, Behcet disease or juvenile idiopathic arthritis&#xD;
&#xD;
          -  Chronic immunomodulatory treatment with anti-TNF, anti-IL6 or anti-IL17 agents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with more than one biological agent.&#xD;
&#xD;
          -  Cancer diagnosis during the last 5 years, bone marrow transplant or solid organ&#xD;
             recipient, HIV diagnosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elvira Balcells, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Red de Salud UC Christus</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

